Target (CBDY) Cost of Revenue (2016 - 2026)
Target (CBDY) reported Cost of Revenue of $687655.0 for Q1 2026, up 9.22% year-over-year from $629612.0 in Q1 2025, and up 53.5% quarter-over-quarter from $447991.0 in Q4 2025.
Target (CBDY) Cost of Revenue (2016 - 2026) Analysis & Trends
Target (CBDY) has 10 years of Cost of Revenue data on file, last reported at $687655.0 in Q1 2026.
- Cost of Revenue for Q1 2026 came in at $687655.0, up 9.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 21.58% YoY), and the FY2025 annual result was $1.8 million, down 36.74% from the prior year.
- Cost of Revenue climbed to $687655.0 in Q1 2026 per CBDY's latest filing, from $447991.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $1.2 million in Q4 2023 and troughed at -$109461.0 in Q1 2023.
- A 5-year average of $550302.3 and a median of $500303.0 in 2025 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2023 and 2024: Cost of Revenue sank 119.44% in 2023, then jumped 1113.84% in 2024.
- A 5-year view of Cost of Revenue shows it stood at $386613.6 in 2022, then surged by 221.16% to $1.2 million in 2023, then sank by 37.39% to $777447.0 in 2024, then tumbled by 42.38% to $447991.0 in 2025, then jumped by 53.5% to $687655.0 in 2026.
- Business Quant data shows CBDY's Cost of Revenue at $687655.0 in Q1 2026, $447991.0 in Q4 2025, and $235291.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 696.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 641.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 133.40 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 34.44 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 13.80 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 586.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 155.56 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 52.68 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 222.00 Mn |
| 10 | Target | - | - | 191,787.00 | 687,655.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 687,655.00 |
| Mar 31, 2026 | 687,655.00 |
| Dec 31, 2025 | 447,991.00 |
| Dec 31, 2025 | 447,991.00 |
| Sep 30, 2025 | 235,291.00 |
| Sep 30, 2025 | 235,291.00 |
| Jun 30, 2025 | 500,303.00 |
| Jun 30, 2025 | 500,303.00 |
| Mar 31, 2025 | 629,612.00 |
| Mar 31, 2025 | 629,612.00 |
| Dec 31, 2024 | 777,447.00 |
| Dec 31, 2024 | 777,447.00 |
| Sep 30, 2024 | 173,006.00 |
| Sep 30, 2024 | 173,006.00 |
| Jun 30, 2024 | 806,184.00 |
| Jun 30, 2024 | 806,184.00 |
| Mar 31, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Dec 31, 2023 | 1.24 Mn |